Comparative Pharmacology
Head-to-head clinical analysis: ALFENTA versus DOLENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFENTA versus DOLENE.
ALFENTA vs DOLENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing cAMP production, leading to reduced neuronal excitability and pain transmission.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Clinical Note
moderateAlfentanil + Torasemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide."
Clinical Note
moderateAlfentanil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid."
Clinical Note
moderateAlfentanil + Furosemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide."
Clinical Note
moderateAlfentanil + Bumetanide
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide."